Company: HCWB
Filing Date: 2025-02-21
Form Type: DEF 14A
Source: 0001193125-25-032115
Chunk: 66

Company: HCW Biologics Inc.
Filing Date: 2025-02-21
Form: DEF 14A
Chunk 66
---
 Notice, the Investor
shall have received the Closing Certificate executed by an executive officer of the Company and to the effect that all the conditions to such Closing shall have been satisfied as of the date of each such certificate.

(k) . The Common Stock must be DWAC Eligible and not subject to a “DTC chill.”

(l) . All reports, schedules, registrations, forms, statements, information, and other documents required to have been
filed by the Company with the SEC pursuant to the reporting requirements of the Exchange Act (other than Forms 8-K) shall have been filed with the SEC within the applicable time periods prescribed for such
filings under the Exchange Act.

(m) . The Transfer Agent Instruction Letter shall have been
executed and delivered by the Company to the Transfer Agent and acknowledged and agreed to in writing by the Transfer Agent, and the Company shall have no knowledge of any fact or circumstance that would prevent the Transfer Agent from complying
with the terms of the Transfer Agent Instruction Letter.

(n) . The Put Shares shall have been approved by the
Investor’s prime broker or designated clearing firm for deposit to its account with the Depository Trust Company system.

(o) . No statute, regulation, order, guidance, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal, state, local or foreign court or governmental authority of competent
jurisdiction, including, without limitation, the SEC, which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents.

(p) . The Company shall cause to be delivered to the Investor a written opinion or opinions of counsel reasonably
satisfactory to the Investor, in form and substance reasonably satisfactory to the

- A-19 -

Investor and its counsel, relating to the availability and effectiveness of the Registration Statement, as supplemented by any prospectus supplement or amendment thereto, and regarding the
Company’s compliance with the laws of the State of Delaware and the federal securities laws of the United States in the issuance, sale and registration of the Put Shares and Commitment Shares and entrance into the transaction documents.

(q) . Without the prior written consent of the Investor, from any Put Date until the end of any Standstill
Period the Company shall not enter into any Variable Rate Transaction or have in force and effect any existing Variable Rate Transaction. For purposes of this Agreement, “” means a transaction in which the
Company (i) issues or sells any equity or